Idarrubicina Accord (Idarubicin Hydrochloride)

Idarubicin is used in chemotherapy protocols targeting acute leukemias.

• Acute Myeloid Leukemia (AML): used to achieve complete remission by inducing cytotoxicity in rapidly dividing myeloid blasts.
• Acute Lymphoblastic Leukemia (ALL): incorporated into induction and consolidation regimens to eradicate lymphoid blasts and improve survival outcomes.
• Relapsed or refractory leukemia: employed as a salvage agent when previous chemotherapy has not achieved adequate disease control.

• Idarubicin intercalates between DNA base pairs and stabilizes the DNA‑topoisomerase II complex, preventing relegation of DNA strands. This results in double‑strand breaks and apoptosis of rapidly dividing cells. Additionally, the anthracycline core generates free radicals that cause oxidative damage to cellular membranes and organelles, further contributing to its cytotoxic effect on malignant hematopoietic cells. The combined DNA damage and oxidative stress overwhelm repair mechanisms, leading to irreversible cell death.

Idarubicin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
• Alopecia: reversible hair loss affecting scalp and body hair.
• Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, and thrombocytopenia.
• Mucositis: inflammation of the oral and gastrointestinal mucosa.
• Fatigue: generalized tiredness during and after infusion.

Serious or Rare Side Effects

• Cardiotoxicity: irreversible damage to cardiac muscle that may lead to heart failure.
• Severe neutropenia with infection risk: febrile neutropenia requiring urgent medical care.
• Hepatotoxicity: elevated liver enzymes and potential liver dysfunction.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Secondary malignancies: rare development of therapy‑related leukemia or solid tumors.

When using Idarubicin, clinicians should observe specific safety measures and handling guidelines.

• Cardiac assessment: perform baseline and periodic echocardiograms to monitor left ventricular function.
• Hematologic monitoring: check complete blood counts before each cycle to detect myelosuppression.
• Infection control: implement prophylactic antibiotics or growth factors as indicated for neutropenic patients.
• Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks.
• Drug interactions: review concomitant medications for agents that may increase cardiotoxicity or myelosuppression.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with several drugs, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Anthracycline combination: concurrent use with other anthracyclines markedly increases cardiotoxic risk.
• CYP3A4 inhibitors: strong inhibitors (e.g., ketoconazole) may raise idarubicin plasma levels, enhancing toxicity.
• Cardiac glycosides: co‑administration can exacerbate arrhythmias and cardiac dysfunction.

Moderate Interactions (Monitor Closely)

• Anticoagulants: increased bleeding risk due to thrombocytopenia; monitor coagulation parameters.
• Radiotherapy: overlapping toxicities to bone marrow; adjust dosing schedules.
• Cytokine‑inducing agents: may augment free‑radical formation, heightening oxidative damage.